Accrued Expenses and Restructuring Reserve (Tables)

6 Months Ended

Jun. 30, 2019

Accrued Expenses and Restructuring Reserve [Abstract]

Accrued expenses and other liabilities consist of the following:

	As of June 30, 2019		As of December 31, 2018
Accrued research and development costs	$	91,229	$	71,329
Accrued professional fees		242,732		421,617
Accrued compensation		304,225		54,269
Accrued other		–		46,674
Accrued rent		–		8,000
Total	$	638,186	$	601,889

Restructuring Reserve

	As of June 30, 2019		As of December 31, 2018
Restructuring reserve (1)	$	1,283,875	$	–
Total	$	1,283,875	$	–

(1)

Restructuring reserve relates to the severance costs incurred by Edge Therapeutics prior to the merger transaction and assumed by the Company as part of the purchase accounting, but not yet paid. The severance costs continue through September 2020. For the six months ended June 30, 2019, the Company paid $786,396 of restructuring expense which was previously recorded on Edge Therapeutics financials.